Interleukin 28B Polymorphism Predicts Pegylated Interferon Plus Ribavirin Treatment Outcome in Chronic Hepatitis C Genotype 4
Stella De Nicola(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Massimo Colombo(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Raffaele De Francesco(University of Milan), Maria Francesca Donato(University of Milan), Luca Valenti(University of Milan), E. Galmozzi(University of Milan), Roberta D’Ambrosio(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Alessio Aghemo, Maria Grazia Rumi(University of Milan), R. Soffredini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Gian Maria Prati(University of Milan), Cristina Cheroni(Human Technopole)
Cited by 83
Related Papers
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
|Journal of Hepatology|2001|4.1k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
|Journal of Hepatology|2024|1.6k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Annals of Hepatology|2023|789